drugset / Trial / NCT06817525
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
RandomizedParallel-groupOpen-labelTreatment
Summary
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
Timeline
- Start
- 2024-11-06
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nab-P | Unknown | 125 mg/m2 | — |
| Comparator | Nab-P | Unknown | 125 mg/m2 | — |
| Comparator | Nab-P | Unknown | 260 mg/m2 | — |
| Comparator | Nab-P | Unknown | 260 mg/m2 | — |
| Comparator | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Comparator | Carboplatin | Small molecule | — | — |